Foundation Medicine, Inc.
Foundation Medicine, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Foundation Medicine, Inc..
Foundation Medicine, Inc. is a company.
Key people at Foundation Medicine, Inc..
Foundation Medicine, Inc. (FMI) is a molecular information company specializing in precision oncology, developing comprehensive genomic profiling (CGP) tests that analyze over 300 cancer-driving genes to match patients with targeted therapies.[1] Acquired fully by Roche in 2018 and operating as an independent affiliate, FMI serves oncologists, patients, and pharmaceutical developers by enabling data-driven treatment decisions and accelerating new cancer therapy development, with over 1,700 employees across North America and Germany, headquartered in Cambridge, Massachusetts.[1] Its growth reflects the rising demand for personalized medicine, positioning CGP as a potential global standard in cancer care.[1]
Founded in 2010, Foundation Medicine emerged amid the genomics revolution to address gaps in cancer treatment personalization.[1] The company's idea stemmed from advancing cancer genomics, quickly gaining traction by generating genomic profiles for thousands of patients and contributing to research efforts like the NCI Genomic Data Commons.[1][2] A pivotal moment came in 2018 with Roche's complete acquisition, transforming FMI into an independent affiliate while leveraging Roche's global resources for expanded impact.[1]
Foundation Medicine rides the wave of precision oncology and genomics, where falling sequencing costs and AI-driven analysis enable tailored cancer therapies amid a market projected to grow rapidly due to aging populations and immunotherapy advances.[1] Its timing aligns with post-2010 NGS (next-generation sequencing) breakthroughs and regulatory shifts favoring companion diagnostics, amplified by Roche's ecosystem for scaling CGP globally.[1] FMI influences the landscape by standardizing genomic insights, fueling pharma pipelines, and contributing to public datasets, thus bridging research, clinical practice, and drug innovation.[1][2]
FMI is poised to expand CGP adoption as standard care, integrating multi-omics data and AI for even more predictive profiling amid trends like liquid biopsies and combination therapies.[1] Evolving regulations and payer reimbursements will shape its path, potentially amplifying Roche synergies for global dominance in precision oncology. As genomics matures, FMI's role could evolve from profiling pioneer to ecosystem orchestrator, driving more effective, personalized cancer outcomes and reinforcing its foundational impact in the field.[1]
Key people at Foundation Medicine, Inc..
